Rezdiffra sales re-accelerate, but market creation is expensive
- Madrigal generated $364.3M in Q2 2026 net sales from Rezdiffra, showing strong growth.
- The company continues to invest heavily, with Q2 SG&A reaching $289.4M to expand its sales force.
- Madrigal recently secured UK authorization for Rezdiffra and started Phase 1 trials for its oral GLP-1.
- The bear case remains focused on high operating costs delaying the path to profitability.
- A U.S. patent protecting the commercial dosing approach runs to February 2045.
A blockbuster with a burn rate
Madrigal has done the hard part that many biotechs never reach. It launched Rezdiffra and created large demand in a new drug market. Q2 2026 net sales were $364.3M, which showed a strong re-acceleration and answered previous concerns about flattening momentum.
The bull case is simple. Rezdiffra is first in a large disease area, NASH, now often called MASH. The drug treats patients with moderate to advanced liver scarring before cirrhosis. Madrigal estimates there are roughly 460,000 U.S. patients under specialist care, making the long-term market opportunity significant.
The bear case centers on the cost of building this market. Madrigal is spending heavily to defend its lead. In Q2 2026, SG&A jumped to $289.4M, driven by direct-to-consumer marketing and a new field force focused on endocrinologists. The company also continues to spend on pipeline deals, like the recent licensing of MGL-0795.
The key tension is no longer whether Rezdiffra can sell. It can. The open question is how much cash Madrigal must spend before sales growth, payer discounts, and operating costs line up into steady profits.
Selling through liver specialists
Madrigal makes money from one product: Rezdiffra. It sells the drug in the U.S. through a limited specialty pharmacy network. The main prescribers are hepatologists and gastroenterologists, doctors who treat liver and digestive diseases. The company is now expanding to target endocrinologists as well.
This is a first-in-disease launch. That means Madrigal must teach doctors how to find the right patients, help offices process prescriptions, and work with payers on coverage. That work can create a strong early lead, but it costs a lot of money upfront.
The moat has improved recently. Madrigal has a U.S. patent on the commercial weight-based dosing regimen for Rezdiffra that expires in February 2045. If that patent holds up, it extends the protected life of the drug from a normal launch window into a much longer franchise.
The next layer is geography. All current revenue is from the U.S. Madrigal plans to sell directly in Europe after expected regulatory decisions, starting with Germany. That could add growth, but it also brings new launch costs and reimbursement risks in each country.
One drug, many follow-ons
Rezdiffra
Rezdiffra is the only commercial product and the whole revenue base today. It is approved for noncirrhotic NASH with moderate to advanced liver fibrosis.
F4 cirrhosis expansion
Madrigal is testing Rezdiffra in compensated NASH cirrhosis, called F4 disease. A pivotal outcomes trial is expected to read out in 2027 and could expand the addressable market.
MGL-2086
MGL-2086 is Madrigal's oral GLP-1 program. It entered Phase 1 trials in June 2026 and is meant to support future combination treatments with Rezdiffra.
Ervogastat
Ervogastat is a DGAT2 inhibitor brought in to build combination therapy options. Madrigal has discussed Phase 2 combination work with Rezdiffra.
MGL-0795
Formerly ARO-PNPLA3, this siRNA program was recently in-licensed. It adds another mechanism to the NASH pipeline, with plans for a Phase 2 combination trial.
U.S. sales for now
For Q2 2026, Madrigal reported $364.3M of product revenue. The internal segment view treats all current revenue as U.S. Rezdiffra sales. Europe is included as a zero-revenue launch option as the company prepares for international expansion.
What could break the thesis
Launch growth slows
High impact · Medium oddsRezdiffra sales re-accelerated in Q2 2026, but the company must sustain this momentum as it targets a broader physician base. If growth slows before the company scales down its marketing, the stock story changes fast.
Gross-to-net pressure
High impact · Medium oddsGross-to-net means the gap between list-price sales and what Madrigal keeps after rebates, discounts, and fees. Management previously projected this discount to be in the mid-to-high 30% range for 2026. If the discount rises above that, profit becomes harder even if prescriptions grow.
Market-building costs stay too high
High impact · High oddsMadrigal is paying to create the NASH treatment market. Q2 2026 SG&A jumped to $289.4M, driven by commercial work and field force expansion. If the company needs this level of spending for years, the path to sustained profit gets pushed out.
Pipeline bets disappoint
Medium impact · Medium oddsMadrigal is using Rezdiffra cash flow to build a broad NASH pipeline, recently licensing MGL-0795. If MGL-2086, ervogastat, or MGL-0795 fail in trials, the company may have spent heavily without extending its long-term lead.
Future competition changes the market
High impact · Medium oddsNASH is a large market, so other drug makers will keep trying. GLP-1 drugs and other mechanisms could take share or pressure pricing over time. Madrigal's own oral GLP-1 strategy is meant to reduce this risk, but it is still early.
In one breath
What does Madrigal Pharmaceuticals do?
Madrigal sells Rezdiffra, a drug for certain NASH patients with moderate to advanced liver scarring. It is also building a pipeline of follow-on and combination treatments in the same disease area.
Why is Rezdiffra important?
Rezdiffra was the first approved drug for its target NASH population. That gives Madrigal a first-mover lead with doctors, payers, and specialty pharmacies.
Is Madrigal profitable?
No, not as of Q2 2026. The company is spending heavily on marketing, a growing sales force, and pipeline deals to secure its market lead.
What is the next big catalyst for MDGL?
The next 12 months center on Rezdiffra sales growth, the early launch performance in Europe, and updates on Phase 2 combination trials for MGL-0795. The F4 cirrhosis outcomes trial is expected to read out in 2027.
